FILGRASTIM
Priapism Due to Sickle Cell Disease
Vanderbilt University Medical Centerprotein_peptidePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Priapism Due to Sickle Cell Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hydroxyurea Vanderbilt University Medical Center | Phase 2 | B |
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →